We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
In vitro evaluation of global coagulation potentials in the co‐presence of plasma‐derived factors Viia/X products (Byclot<sup>®</sup>) and emicizumab in patients with haemophilia A and inhibitors and acquired haemophilia A: A pilot study.
- Authors
Nakajima, Yuto; Takami, Eisuke; Nakano, Hirotoshi; Nogami, Keiji
- Abstract
In the cell-based model of thrombin generation, it was described that the procoagulant activity of rFVIIa was mostly related to FX activation on the surface of activated platelets.10 In the absence of platelets, it may not be optimal for evaluating FX activation and pd-FVIIa/FX. Theoretically, pd-FVIIa/FX administration would be concomitantly haemostatically effective for breakthrough bleedings in PwHA with inhibitor receiving emicizumab prophylaxis. The CT+CFT in the co-presence of emicizumab and pd-FVIIa/FX (.375 and.75 µg/ml) were roughly similar to that of emicizumab and rFVIIa (1.1 µg/ml), but that in the co-presence of pd-FVIIa/FX (1.5 µg/ml) shortened compared to rFVIIa. In ROTEM, the CT+CFT obtained by the addition of pd-FVIIa/FX (.375 µg/ml) appeared to be comparable to that by rFVIIa (1.1 µg/ml), and that obtained by the addition of pd-FVIIa/FX (.75 and 1.5 µg/ml) were shorter than that by rFVIIa.
- Subjects
EMICIZUMAB; PLATELET-rich plasma; BISPECIFIC antibodies; THROMBIN; BLOOD coagulation factor VIII antibodies; BLOOD coagulation; THROMBIN receptors
- Publication
Haemophilia, 2022, Vol 28, Issue 5, pe149
- ISSN
1351-8216
- Publication type
Article
- DOI
10.1111/hae.14650